Form 4: BridgeBio Pharma Director Acquires Stock Options

James C. Momtazee, a director of BridgeBio Pharma, Inc., acquired stock options for 26,014 shares on June 21, 2024.

Summary

• On June 21, 2024, James C. Momtazee, a director at BridgeBio Pharma, Inc. (BBIO), was granted stock options to purchase 26,014 shares of common stock.
• The exercise price of these options is $27.36 per share.
• The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.
• The expiration date for these options is June 20, 2034.
• Following the transaction, Momtazee directly owns 26,014 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes long-term commitment from the director.

Future Outlook

The vesting schedule suggests an expectation of continued service and contribution from the director over the next three years.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of management and shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options to incentivize their directors and executives.
• The vesting schedule and exercise price are generally in line with industry practices for similar-sized companies.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates